News Ipsen

Stocks

IPN

FR0010259150

Pharmaceuticals

Real-time Euronext Paris Other stock markets 11:35:29 2026-07-07 EDT			5-day change	1st Jan Change
168.40 ^EUR	-0.65%		-0.24%	+41.51%

04:45am	AlphaValue/Baader Europe Cuts Ipsen Price Target Amid Future Patent Expiries, Mid-term Risks	MT
07-06	Ipsen: Reassessing mid-term risks

All News

Mentions Relevance

04:45am	AlphaValue/Baader Europe Cuts Ipsen Price Target Amid Future Patent Expiries, Mid-term Risks	MT
07-06	IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2026	GL
07-06	Ipsen: Reassessing mid-term risks
07-06	BlackRock tops 5% stake in Ipsen
07-03	IPSEN - Buy-back programme - Art 5 of MAR - Week 26- 2026	GL
07-01	AlphaValue/Baader Europe Downgrades Ipsen to Add, Lifts PT	MT
07-01	Oddo BHF still neutral on Ipsen after a new acquisition
07-01	Ipsen to Acquire Memo Therapeutics in Up to EUR700 Million Deal	MT
07-01	Ipsen lines up another bolt-on acquisition
07-01	French biotech Ipsen to buy Memo Therapeutics for $230 million upfront	RE
07-01	Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio	GL
06-30	Ipsen Extends Its Rally, Backed by Oddo BHF
06-29	Health Care Flat as Risk Appetite Rebounds - Health Care Roundup	DJ
06-29	RBC Capital weighs in on Ipsen acquisition
06-29	French biotech company Ipsen to buy Kartos Therapeutics for $450 million	RE
06-29	Ipsen strengthens its hematology franchise with the acquisition of Kartos Therapeutics
06-29	Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion	MT
06-29	Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline	GL
06-28	Ipsen S.A. entered into a definitive merger agreement to acquire Kartos Therapeutics, Inc. for $1.8 billion.	CI
06-22	IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2026	GL
06-15	IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2026	GL
06-09	Ipsen : welcomes the European Union’s publication of the Joint Clinical Assessment for Ojemda® (tovorafenib)	PU
06-08	IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2026	GL
06-05	HC Wainwright Starts Ipsen Coverage with Buy Rating	MT
06-01	Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns	RE